Study of Specimens From Young Patients With Neuroblastoma

Children's Oncology Group

Status: Completed

Conditions: Regional Neuroblastoma; Localized Unresectable Neuroblastoma; Stage 4S Neuroblastoma; Localized Resectable Neuroblastoma

Treatments: Other: laboratory biomarker analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT00958659

ANBL08B1 (Other Identifier)

NCI-2011-02190 (Registry Identifier)

COG-NB-2008-01 (Other Identifier)

COG-ANBL08B1 (Other Identifier)

Details and patient eligibility

About

This research trial studies specimens from young patients with neuroblastoma. Studying the genes expressed in specimens from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

Full description

PRIMARY OBJECTIVES:

I. Establish a robust messenger ribonucleic acid (mRNA) gene expression classifier for improved outcome prediction in children with neuroblastoma by using real-time polymerase chain reaction (PCR) to quantify mRNA levels from genes that have been shown in at least 2 independent studies to have predictive power.

II. Identify microRNA (miRNA) patterns that have prognostic significance in neuroblastoma (NB) as accumulating evidence indicates that alterations in miRNA expression play a critical role in tumorigenesis and can be used in prognostic evaluation.

III. To perform an integrated analysis of the established microRNA classifier with our mRNA signature to determine whether it results in even better classification of NB tumors.

OUTLINE:

Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.

Enrollment: 350 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosis of primary Neuroblastoma

  • Untreated disease

• RNA samples from primary untreated NB-tumors available in Children's Oncology Group (COG) repository

  • At least 60% tumor cells

• At least 2 years of follow-up from the date of diagnosis

• Full clinical and biological annotation

Trial design

350 participants in 1 patient group

Ancillary-Correlative (gene expression profiling)

Description:

Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.

Treatment:

Other: laboratory biomarker analysis